Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription medicines, principally for hospital acute care, gastroenterology and oncology markets. Its U.S. portfolio includes Acetadote for acetaminophen poisoning, Caldolor for… From the company’s description.
Over the twelve months to Jun 30, 2026, Cumberland Pharmaceuticals Inc. reported revenue of $22.30M, down 47.0% from a year earlier, and a net loss of $10.94M. Its operating margin was −42.3%, and operations generated $0.75M in cash. In fiscal 2025, it reported revenue of $44.52M, up 17.6% from fiscal 2024, and a net loss of $2.86M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cumberland Pharmaceuticals Inc. does
In the company’s own words
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription medicines, principally for hospital acute care, gastroenterology and oncology markets. Its U.S. portfolio includes Acetadote for acetaminophen poisoning, Caldolor for pain and fever, Kristalose for constipation, Sancuso for chemotherapy-related nausea and vomiting, Vaprisol for hyponatremia, Vibativ for serious bacterial infections, and Talicia for H. pylori infection. The company promotes products through hospital, field and oncology sales teams, while international partners register and commercialize medicines in their territories; its primary U.S. customers are wholesale pharmaceutical distributors. Cumberland also develops ifetroban, a clinical-stage candidate being studied for Duchenne muscular dystrophy-associated cardiomyopathy, systemic sclerosis and idiopathic pulmonary fibrosis, and its majority-owned subsidiary Cumberland Emerging Technologies collaborates with academic institutions on early-stage product development. The company reported approximately 60 sales professionals in 2025. Its website is www.cumberlandpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NASHVILLE,, TN
- Fiscal year end
- December
- CIK
- 1087294
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cumberland Pharmaceuticals Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cumberland Pharmaceuticals Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cumberland Pharmaceuticals Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cumberland Pharmaceuticals Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cumberland Pharmaceuticals Inc.'s last four quarterly filings that the numbers alone won't show?”